ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Embibatinib

Also written as “HS-10382”, “MK-4208” and “TERN-701”.

In Hansoh Pharmaceutical Group’s pipeline, BCR-ABL (STAMP). Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Leukemia, Myeloid, Chronic-Phase, led by 2 companies.

Drug pageEmbibatinib: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 12, 20267 company-led studies, 5 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Groupits history only44 open or runningphase 3since Oct 12, 2026May 6, 2022Feb 2027phase 1 · NCT07933224
Merck31 open or runningphase 2since Nov 8, 2023Nov 8, 2023Nov 30, 2029phase 2 · NCT06163430
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-10382 (STAMP, Terns's TERN-701), phase 1, as of Aug 26, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 8, 2023First study: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFirst studyNCT06163430 · 330 planned · United States, Australia, France and more
  2. Jan 29, 2026Named embibatinibINNProposed as its International Nonproprietary Name in WHO's List 134 · before, HS-10382, MK-4208, TERN-701
  3. Sep 18, 20262 phase 1 studies in HealthyNCT07839000, NCT07838987

Ahead

  1. Nov 30, 2029Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06163430

TargetBeta

“BCR-ABL (STAMP)”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
nilotinibruleNovartisphase 457
asciminibruleNovartisphase 416
olverembatinibruleAscentage Pharma Group Internationalphase 310
TQB3911Sino Biopharmaceuticalphase 11

Studies

All 3 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07839000Healthy · United States1CompletedApr 3, 20268
NCT07838987Healthy · United States1CompletedJun 30, 2026196
NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, France and more2RecruitingNov 30, 2029330

How it is read

Names in the registry

  • “HS-10382”, 2 entries
  • “Embibatinib”, 1 entry
  • “MK-4208”, 1 entry
  • “TERN-701”, 1 entry
  • “HS-10382+Flumatinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.